InnoCare Pharma Initiates Dosing in Phase 1b Trial with SHP2's ICP-189 and EGFR's Furmonertinib Combo

InnoCare Pharma, a prominent biopharmaceutical company, has reached a milestone with the dosing of the first patient in China for a Phase 1b clinical study. The study combines InnoCare's SHP2 allosteric inhibitor, ICP-189, with ArriVent's furmonertinib, an EGFR inhibitor, for patients with advanced or metastatic non-small cell lung cancer (NSCLC). NSCLC constitutes about 85% of all lung cancer cases and is a significant health concern.
The collaboration between InnoCare and ArriVent BioPharma, initiated in July 2023, aims to expedite the clinical trial of the drug combination in China. Furmonertinib is an active drug candidate being studied globally for NSCLC patients with specific EGFR mutations and is approved in China for first-line treatment of adults with certain EGFR mutations. The drug has received Breakthrough Therapy designation from the FDA for the treatment of NSCLC patients with EGFR exon 20 insertion mutations.
ICP-189 is an oral allosteric inhibitor of SHP2, which has shown preliminary efficacy as a monotherapy for solid tumors. The Phase 1b study has escalated the dosage to 120 mg without observing dose-limiting toxicities, demonstrating a favorable pharmacokinetic and safety profile.
Dr. Jasmine Cui, CEO of InnoCare, expressed enthusiasm for the clinical collaboration's progress and emphasized the potential of SHP2 inhibitors to address the unmet medical needs of solid tumor treatments in combination with targeted drugs and immunotherapies. InnoCare is dedicated to developing innovative therapies for cancer and autoimmune diseases, with a global presence and a commitment to bringing new treatments to patients as swiftly as possible.
InnoCare Pharma is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing novel drugs to treat cancer and autoimmune diseases with unmet needs. The company operates branches across China, Hong Kong, and the United States.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!